BETA: Please send your feedback!
PTC Therapeutics
PTCT:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2022
—
About
Biotechnology
Founded 1998
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel medicines using its expertise in RNA biology. The company's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology. It is focused on developing treatments to fundamentally change the lives of patients living with rare genetic disorders. The company was founded by Allan S. Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
website
Headquarters
Executives
| Name | Title | Gender |
| Michael Schmertzler, MBA | Chairman | Male |
| Stuart W. Peltz, PhD | Chief Executive Officer & Class I Director | Male |
| Mark Elliott Boulding | Secretary, Chief Legal Officer & Executive VP | Male |
| Allan Steven Jacobson, PhD | Independent Class III Director | Male |
| Martin Rexroad | Senior Vice President-Human Resources | Male |
| Jane Baj | Head-Investor Relations | Female |
| Neil Gregory Almstead, PhD | Executive VP-Research, Operations & Technology | Male |
| Shane William Charles Kovacs, CFA, MBA | CFO & Head-Corporate Development | Male |
| Tuyen Ong, MD, MBA | Chief Medical Officer | null |
Mindful Investing Summary
PTC Therapeutics - Competitors and Related Companies
How PTC Therapeutics stacks up to its peers in the Biotechnology industry or with competing business segments.
PTC Therapeutics
PTCT:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2022
—
Fate Therapeutics
FATE:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2022
—
Retrophin
RTRX:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2022
—
Xencor
XNCR:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2022
—
Sarepta Therapeutics
SRPT:NAS
Biotechnology
—
MID cap
(—)
—
since start of 2022
—
Novartis
NOVN-CH:SWX
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2022
—